Abu Dhabi: Abu Dhabi Stem Cells Centre (ADSCC) has signed a joint research agreement with Kyoto University – Centre for iPS Cell Research and Application (CiRA) and Rege Nephro- a Japan-based biotech company that specializes in Research, Development and production of renal disease therapeutics.
The collaboration aims to revolutionize diabetes care by developing a new innovative treatment using pancreatic beta cells derived from human induced pluripotent stem cells (iPS cells) iPS cells are obtained from skin or blood cells and then reprogrammed (genetically modified) in highly advanced laboratories. The genetically modified cells will replicate the tissue affected by diabetes.
ADSCC has set up a laboratory at the premises of Kyoto University in Japan to facilitate the joint research.
The joint research will focus on developing iPS cell-derived pancreatic beta cells with enhanced therapeutic efficacy through genetic modifications. The experiment will offer cell therapy options for patients with type 1 diabetes. It will also aid in the screening and testing of potential drugs for type 2 diabetes. It will also help to develop new approaches to manage type 2 diabetes.
Professor Dr. Yendry Ventura, CEO of ADSCC, Adjunct Professor at UAE University, and Research Scientist, said that this partnership is an ideal example of international cooperation. The combined efforts will propel us to achieve excellence in diabetes care for our respective populations and beyond.
Mr. Ventura added that, “At ADSCC, we are on a mission to make a profound impact in the field of diabetes care and cellular therapy globally, and in pursuit of this ambitious journey, we have consciously embarked on this strategic partnership with CiRA and Rege Nephro.”
Professor Kenji Osafune, Head of the Department of Cell Growth and Differentiation at the Centre for iPS Cell Research and Application (CiRA) at Kyoto University and Founder of Rege Nephro, said that “Partnering with ADSCC in this joint research will not only enable us to apply the foundational technology developed in research across the Middle East and North Africa but also establish a pivotal hub for advancing regenerative medicine research through iPS cell technology in the region. CiRA and Rege Nephro share a common mission with ADSCC to provide swift and effective treatments for diabetes, ultimately enhancing the quality of life and prognosis for patients worldwide.”
Prof Dr. Ventura further added that, “With the Department of Health – Abu Dhabi support in innovation and research, we believe this partnership will pave the way for transformative healthcare solutions in our region and beyond. We are also proud to have launched our ADSCC laboratory at Kyoto University premises to facilitate our mission.”
RELATED | DOH Abu Dhabi announces ADSCC as Centre of Excellence in stem cell transplantation